Suven Life Sciences Limited · NSE:SUVEN
Suven Life Sciences — Q2 FY2020 Earnings Presentation
13 slides from Suven Life Sciences's earnings presentation, Nov 14, 2019
Slide 1: SUVEN Life Sciences Ltd – Communication to investors
SUVEN Life Sciences Ltd Communication to investors September 2019 14-Nov-19 2019-20 Q2 results
Slide 2: Risk statement
Risk statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Financial Quick View
FINANCIAL QUICK VIEW Q2-FY20 vs FY 20 YoY Q2-FY19 (6 months) Growth in revenue 191.23% 62.86% Growth in PAT 302.91% 128.21% Growth in EBIDTA 274.57% 114.83% Growth in Pre-R&D EBIDTA 201.43% 88.43% Increase in R&D Costs 18.38% -2.15% R&D to sales 6.49% 5.76% 14-Nov-19 2019-20 Q2 results
Slide 4: Major Profitability Ratios
MAJOR PROFITABILITY RATIOS Q2 Sep 19 FY20 – Half Year PAT to Income 25.83% 26.86% EBIDTA to 41.49% 43.40% Income Cash Flow to 27.82% 29.17% Income Pre-R&D EBITDA 46.73% 49.17% to Income 14-Nov-19 2019-20 Q2 results
Slide 5: Q2 to Q1 Comparison
Q2 to Q1 COMPARISON Revenue - INR Million PAT - INR Million 3,100.00 2,799.00 800.00 722.85 571.43 2,019.93 600.00 2,100.00 400.00 1,100.00 200.00 100.00 - Q1 Jun 19 Q2 Sep 19 Q1 Jun 19 Q2 Sep 19 EBIDTA - INR Million Pre-R&D EBIDTA - INR Million 1,250.00 1,161.20 1,580.00 1,307.84 1,050.00 930.39 1,
Slide 6: Revenue Comparison
REVENUE COMPARISON INR Million 6,000.00 5,000.00 4,818.93 4,000.00 2,958.98 3,000.00 2,799.00 2,000.00 961.08 1,000.00 - Q2 Sep 18 Q2 Sep 19 HY Sep 18 HY Sep 19 14-Nov-19 2019-20 Q2 results
Slide 7: PAT Comparison
PAT COMPARISON INR Million 1,400.00 1,294.28 1,200.00 1,000.00 800.00 722.85 600.00 567.13 400.00 179.41 200.00 - Q2 Sep 18 Q2 Sep 19 HY Sep 18 HY Sep 19 14-Nov-19 2019-20 Q2 results
Slide 8: EBIDTA Comparison
EBIDTA COMPARISON INR Million 2,500.00 2,091.59 2,000.00 1,500.00 1,161.20 973.60 1,000.00 500.00 310.01 - Q2 Sep 18 Q2 Sep 19 HY Sep 18 HY Sep 19 2019-20 Q2 results 14-Nov-19
Slide 9: R & D – Expenditure
R & D – EXPENDITURE INR Million 300.00 283.76 277.66 250.00 200.00 146.64 150.00 123.87 100.00 50.00 - Q2 Sep 18 Q2 Sep 19 HY Sep 18 HY Sep 19 2019-20 Q2 results 14-Nov-19
Slide 10: Pre-R&D EBIDTA
PRE-R&D EBIDTA INR Million 2,500.00 2,369.25 2,000.00 1,500.00 1,307.84 1,257.36 1,000.00 500.00 433.88 - Q2 Sep 18 Q2 Sep 19 HY Sep 18 HY Sep 19 2019-20 Q2 results 14-Nov-19
Slide 11: Pre-R&D Cashflow
PRE-R&D CASHFLOW INR Million 1,800.00 1,683.35 1,600.00 1,400.00 1,200.00 1,000.00 961.58 925.40 800.00 600.00 400.00 358.88 200.00 - Q2 Sep 18 Q2 Sep 19 HY Sep 18 HY Sep 19 2019-20 Q2 results 14-Nov-19
Slide 12: Financial Snapshot
FINANCIAL SNAPSHOT All figures are in INR Million, other than ratios and EPS 2019-20 2019-20 Growth 2018-19 Growth 2019-20 2018-19 Growth % Q2 Q1 % Q2 % HY HY Income 2,799.00 2,019.93 38.57% 961.08 191.23% 4,818.93 2,958.98 62.86% Pre-R&D EBITDA 1,307.84 1,061.41 23.22% 433.88 201.43% 2,369.25 1,257
Slide 13: News Release
News Release • During the period Suven secures 13 product patents covering Australia, Canada, Europe, Eurasia, India, Japan, South Korea, South Africa, Sri Lanka and USA • Updates on CRAMS projects: Total – 117; Phase 1 – 78, Phase 2 – 34, Phase 3 – 1 and commercial – 4. • Enrolled first patient in
Suven Life Sciences — Q2 FY2020 Earnings Presentation on 6ix